The ligand/RAGE axis: Lighting the fuse and igniting vascular stress

Shi Fang Yan, Yoshifumi Naka, Barry Hudson, Kevan Herold, Shi Du Yan, Ravichandran Ramasamy, Ann Marie Schmidt

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Vascular inflammation contributes critically to the initiation and progression of atherosclerosis. These processes are accelerated in hyperglycemia and play key roles in the increased incidence and severity of myocardial infarction and stroke observed in diabetes. Evidence suggests that the ligands of the receptor for advanced glycation endproducts (RAGE), a multiligand member of the immunoglobulin superfamily, interact with this receptor to play important roles in both early development and progression of atherosclerosis and vascular inflammation. Studies in animal models of vascular injury underscored the potent impact of RAGE blockade; administration of ligand-binding decoys of RAGE or antibodies to the receptor reduced the consequences of diabetes, hyperlipidemia, and physical injury to the vessel wall. This review focuses on the ligand repertoire of RAGE, the impact of ligand-RAGE interaction, and the potent effect of RAGE blockade in rodent models of vascular injury.

Original languageEnglish
Pages (from-to)232-239
Number of pages8
JournalCurrent Atherosclerosis Reports
Volume8
Issue number3
DOIs
StatePublished - May 1 2006
Externally publishedYes

Fingerprint

Lighting
Blood Vessels
Ligands
Vascular System Injuries
Atherosclerosis
Inflammation
Hyperlipidemias
Hyperglycemia
Advanced Glycosylation End Product-Specific Receptor
Immunoglobulins
Rodentia
Animal Models
Stroke
Myocardial Infarction
Antibodies
Incidence
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Yan, S. F., Naka, Y., Hudson, B., Herold, K., Yan, S. D., Ramasamy, R., & Schmidt, A. M. (2006). The ligand/RAGE axis: Lighting the fuse and igniting vascular stress. Current Atherosclerosis Reports, 8(3), 232-239. https://doi.org/10.1007/s11883-006-0078-9

The ligand/RAGE axis : Lighting the fuse and igniting vascular stress. / Yan, Shi Fang; Naka, Yoshifumi; Hudson, Barry; Herold, Kevan; Yan, Shi Du; Ramasamy, Ravichandran; Schmidt, Ann Marie.

In: Current Atherosclerosis Reports, Vol. 8, No. 3, 01.05.2006, p. 232-239.

Research output: Contribution to journalArticle

Yan, SF, Naka, Y, Hudson, B, Herold, K, Yan, SD, Ramasamy, R & Schmidt, AM 2006, 'The ligand/RAGE axis: Lighting the fuse and igniting vascular stress', Current Atherosclerosis Reports, vol. 8, no. 3, pp. 232-239. https://doi.org/10.1007/s11883-006-0078-9
Yan, Shi Fang ; Naka, Yoshifumi ; Hudson, Barry ; Herold, Kevan ; Yan, Shi Du ; Ramasamy, Ravichandran ; Schmidt, Ann Marie. / The ligand/RAGE axis : Lighting the fuse and igniting vascular stress. In: Current Atherosclerosis Reports. 2006 ; Vol. 8, No. 3. pp. 232-239.
@article{29e58fc9b74e4dc5bced42e98462971f,
title = "The ligand/RAGE axis: Lighting the fuse and igniting vascular stress",
abstract = "Vascular inflammation contributes critically to the initiation and progression of atherosclerosis. These processes are accelerated in hyperglycemia and play key roles in the increased incidence and severity of myocardial infarction and stroke observed in diabetes. Evidence suggests that the ligands of the receptor for advanced glycation endproducts (RAGE), a multiligand member of the immunoglobulin superfamily, interact with this receptor to play important roles in both early development and progression of atherosclerosis and vascular inflammation. Studies in animal models of vascular injury underscored the potent impact of RAGE blockade; administration of ligand-binding decoys of RAGE or antibodies to the receptor reduced the consequences of diabetes, hyperlipidemia, and physical injury to the vessel wall. This review focuses on the ligand repertoire of RAGE, the impact of ligand-RAGE interaction, and the potent effect of RAGE blockade in rodent models of vascular injury.",
author = "Yan, {Shi Fang} and Yoshifumi Naka and Barry Hudson and Kevan Herold and Yan, {Shi Du} and Ravichandran Ramasamy and Schmidt, {Ann Marie}",
year = "2006",
month = "5",
day = "1",
doi = "10.1007/s11883-006-0078-9",
language = "English",
volume = "8",
pages = "232--239",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - The ligand/RAGE axis

T2 - Lighting the fuse and igniting vascular stress

AU - Yan, Shi Fang

AU - Naka, Yoshifumi

AU - Hudson, Barry

AU - Herold, Kevan

AU - Yan, Shi Du

AU - Ramasamy, Ravichandran

AU - Schmidt, Ann Marie

PY - 2006/5/1

Y1 - 2006/5/1

N2 - Vascular inflammation contributes critically to the initiation and progression of atherosclerosis. These processes are accelerated in hyperglycemia and play key roles in the increased incidence and severity of myocardial infarction and stroke observed in diabetes. Evidence suggests that the ligands of the receptor for advanced glycation endproducts (RAGE), a multiligand member of the immunoglobulin superfamily, interact with this receptor to play important roles in both early development and progression of atherosclerosis and vascular inflammation. Studies in animal models of vascular injury underscored the potent impact of RAGE blockade; administration of ligand-binding decoys of RAGE or antibodies to the receptor reduced the consequences of diabetes, hyperlipidemia, and physical injury to the vessel wall. This review focuses on the ligand repertoire of RAGE, the impact of ligand-RAGE interaction, and the potent effect of RAGE blockade in rodent models of vascular injury.

AB - Vascular inflammation contributes critically to the initiation and progression of atherosclerosis. These processes are accelerated in hyperglycemia and play key roles in the increased incidence and severity of myocardial infarction and stroke observed in diabetes. Evidence suggests that the ligands of the receptor for advanced glycation endproducts (RAGE), a multiligand member of the immunoglobulin superfamily, interact with this receptor to play important roles in both early development and progression of atherosclerosis and vascular inflammation. Studies in animal models of vascular injury underscored the potent impact of RAGE blockade; administration of ligand-binding decoys of RAGE or antibodies to the receptor reduced the consequences of diabetes, hyperlipidemia, and physical injury to the vessel wall. This review focuses on the ligand repertoire of RAGE, the impact of ligand-RAGE interaction, and the potent effect of RAGE blockade in rodent models of vascular injury.

UR - http://www.scopus.com/inward/record.url?scp=33646435289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646435289&partnerID=8YFLogxK

U2 - 10.1007/s11883-006-0078-9

DO - 10.1007/s11883-006-0078-9

M3 - Article

C2 - 16640960

AN - SCOPUS:33646435289

VL - 8

SP - 232

EP - 239

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 3

ER -